Method for diagnosing cell proliferation disorders having a neoactive mutation at residue 97 of isocitrate dehydrogenase 1
Methods and compositions for treating and evaluating subjects having a neoactive mutation at residue 97 of IDH1 or 137 of IDH2.
1. A method of diagnosing a subject having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder characterized by:
(a) the presence, distribution, or level of an isocitrate dehydrogenase 1 enzyme having a mutation at residue 97 wherein the glycine residue has been replaced with an aspartic acid residue (IDH1-G97D), which has 2-hydroxyglutarate (2HG) neoactivity, wherein 2HG neoactivity is the ability to convert alpha ketoglutarate to 2-hydroxyglutarate, or
(b) elevated levels of 2HG due to the presence of IDH1-G97D mutant enzyme having 2HG neoactivity,
wherein said method comprises analyzing the presence, distribution, or level of 2HG in a tissue, product, or bodily fluid of said subject by a chromatographic method, wherein an increased presence, distribution, or level of 2HG indicates the presence of the cell proliferation-related disorder,
thereby diagnosing the subject for the cell proliferation-related disorder.
2. A method of evaluating a subject for the susceptibility to a cell proliferation-related disorder characterized by:
(a) the presence, distribution, or level of an isocitrate dehydrogenase 1 enzyme having a mutation at residue 97 wherein the glycine residue has been replaced with an aspartic acid residue (IDH1-G97D), which has 2-hydroxyglutarate (2HG) neoactivity, wherein 2HG neoactivity is the ability to convert alpha ketoglutarate to 2-hydroxyglutarate, or
(b) elevated levels of 2HG due to the presence of IDH1-G97D mutant enzyme having 2HG neoactivity,
wherein said method comprises analyzing the presence, distribution, or level of 2HG in a tissue, product, or bodily fluid of said subject by a chromatographic method,
wherein an increased presence, distribution, or level of 2HG indicates the susceptibility of the subject to the cell proliferation-related disorder,
thereby evaluating the subject for the susceptibility to the cell proliferation-related disorder.
3. The method of claim 1 or 2 , wherein said cell proliferation-related disorder is selected from the group consisting of colon cancer and glioma.
4. The method of claim 1 or 2 , wherein said bodily fluid is blood or plasma.
5. The method of claim 1 or 2 , wherein the chromatographic method is LC-MS.
6. The method of claim 1 or 2 , wherein the chromatographic method is GC-MS.
7. A method of evaluating a subject for the susceptibility to a cell proliferation-related disorder, said method comprising analyzing the subject or a sample from the subject for the presence, distribution, or level of 2-hydroxyglutarate (2HG), wherein the subject does not have or is not diagnosed as having 2-hydroxyglutaric aciduria, and wherein the subject has an isocitrate dehydrogenase 1 enzyme having a mutation at residue 97 wherein the glycine residue has been replaced with an aspartic acid residue (IDH1-G97D), and evaluating bodily fluid of the subject by a chromatographic method to identify 2HG, wherein an increased presence, distribution, or level of 2HG indicates the susceptibility of the subject to the cell proliferation-related disorder, thereby evaluating the subject for the susceptibility to the cell proliferation-related disorder.
8. A method of diagnosing a subject having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder, said method comprising analyzing the subject or a sample from the subject for the presence, distribution, or level of 2-hydroxyglutarate (2HG), wherein the subject is not having or not diagnosed as having 2-hydroxyglutaric aciduria, and wherein the subject has an isocitrate dehydrogenase 1 enzyme having a mutation at residue 97 wherein the glycine residue has been replaced with an aspartic acid residue (IDH1-G97D), and evaluating bodily fluid of the subject by a chromatographic method to identify 2HG, wherein an increased presence, distribution, or level of 2HG indicates the presence of the cell proliferation-related disorder in the subject, thereby diagnosing the subject for the cell proliferation-related disorder.
9. The method of claim 7 or 8 , wherein said cell proliferation-related disorder is selected from the group consisting of colon cancer, glioma, prostate cancer, acute lymphoblastic leukemia, myelodysplasia, myelodysplastic syndrome, acute lymphoblastic leukemia and acute myelogenous leukemia.
10. The method of claim 7 or 8 , wherein the bodily fluid of the subject is blood, plasma, or urine.
11. The method of claim 7 or 8 , wherein the chromatographic method is LC-MS.
12. The method of claim 7 or 8 , wherein the chromatographic method is GC-MS.